newsfilter
← Latest News
GlobeNewswire·

Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Company anticipates topline, interim data for RSV le